The University of Minnesota has filed a lawsuit that alleges patent infringement by a drug company related to the sale of blockbuster medications that can cure patients of hepatitis C.
In a lawsuit filed Monday, the U alleges that California-based Gilead Sciences has infringed, and continues to infringe, on the university's intellectual property rights by selling three medicines that contain the drug sofosbuvir.
The drug is included in the brand-name medications Sovaldi and Harvoni, which health insurers last year called out as exemplifying concerns over the growing cost of specialty pharmaceuticals. The drugs can cure many patients, but were launched with price tags of roughly $1,000 per pill, or nearly $90,000 for a full three-month treatment.
"Gilead has reaped tens of billions of dollars in sales of those drugs, without the University's authorization and without compensating the University," the lawsuit states. "The University invests heavily in the important and groundbreaking work of its professors, and it takes seriously its role in defending their and the University's intellectual property rights."
In a statement, Gilead Sciences said it believes the U's patent is invalid.
"Gilead strongly believes that it has the sole right to commercialize sofosbuvir in the U.S.," the company said. "We believe the University of Minnesota's patent is invalid and is not infringed by the sale of Gilead's medicines for chronic hepatitis C."
In its lawsuit, the U said the drugs are covered by patent rights assigned to the university by Dr. Carston Wagner, an endowed chair in medicinal chemistry at the U's college of pharmacy.
According to the lawsuit, Wagner received in August 2014 the patent in question, which has been assigned to the U.
